Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764575 | 0.79 | ANPEP (0.48) | ERAP2ANPEPMMELAP3ERAP1 | |
| SCHEMBL1764402 | 0.75 | HSD17B10 (0.52) | MME | |
| SCHEMBL7614011 | 0.73 | HSD17B10 (0.57) | ERAP2ANPEPMME | |
| SCHEMBL5916388 | 0.71 | ERAP2 (0.50) | ERAP2ANPEPLAP3ERAP1 | |
| SCHEMBL11252444 | 0.68 | TSHR (0.64) | MME | |
| SCHEMBL5058107 | 0.67 | CYP1A2 (0.61) | ERAP2ANPEPFOLH1LAP3ERAP1 | |
| SCHEMBL2043743 | 0.67 | ANPEP (0.50) | ERAP2ANPEPMMELAP3ERAP1 | |
| SCHEMBL1764058 | 0.66 | ANPEP (0.57) | ERAP2ANPEPMMELAP3ERAP1 | |
| SCHEMBL12145012 | 0.66 | CPA3 (0.55) | ERAP2ANPEPLAP3ERAP1 | |
| SCHEMBL12018336 | 0.66 | CES1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ERAP2 4566/4885ANPEP 2038/4885MME 3670/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | ERAP2 4514/4885ANPEP 2062/4885MME 3490/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ERAP2 4514/4885ANPEP 2062/4885MME 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.